Update on FDA's Regulation of Cannabis-Based Compounds Webinar
Keller and Heckman Food and Drug partners Evangelia Pelonis and Frederick Stearns hosted a complimentary webinar focusing on FDA's regulation of cannabis-based compounds on June 11, 2019. Companies that plan to or that currently manufacture and/or market products containing cannabis and/or cannabis-derived compounds such as cannabidiol (CBD) as ingredients in foods, dietary supplements, or cosmetics attended this webinar to understand the latest developments in FDA's regulation of these types of products.
Webinar agenda items included:
- Current legal status of cannabis and cannabis-based compounds in FDA regulated products, including:
- Current status as controlled substances under the Federal Controlled Substances Act
- Impact of the Agricultural Improvement Act of 2018 (the Farm Bill)
- Legal basis for FDA's position (stated in December 2018) that it is unlawful to introduce food containing added CBD into interstate commerce or to market CBD products as, or in, food and dietary supplements
- Practical tips for companies to navigate this space in light of the legal and regulatory uncertainties that exist
- Report on FDA's public hearing held on May 31: Mr. Stearns attended the hearing which FDA scheduled to obtain scientific data and information about the safety, manufacturing, product quality, marketing, labeling and sale of products containing cannabis or cannabis-based compounds; the information collected is expected to guide FDA's future regulation of these products.
Date: Tuesday, June 11, 2019
Time: 1:00 PM - 2:00 PM EST